Shia Jinru, Ellis Nathan A, Klimstra David S
Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY 10021, New York, USA.
Virchows Arch. 2004 Nov;445(5):431-41. doi: 10.1007/s00428-004-1090-5. Epub 2004 Sep 29.
Since the development of monoclonal antibodies against the MSH2 protein by Leach et al. in 1996, a series of investigations has been undertaken to determine the utility of immunohistochemical detection of DNA mismatch repair (MMR) gene proteins in the identification of hereditary or sporadic colorectal tumors with microsatellite instability. These studies, however, have been performed with different aims and on different patient populations. Interpretation of these immunohistochemical data relies on a thorough understanding of the biological and technical factors that affect the detection of MMR proteins. In this review, we analyze the data from the published research studies, pointing out the various factors affecting immunohistochemical detection of MMR proteins and projecting the utility of immunohistochemistry in different clinical settings.
自1996年利奇等人开发出针对MSH2蛋白的单克隆抗体以来,已开展了一系列调查,以确定免疫组织化学检测DNA错配修复(MMR)基因蛋白在识别具有微卫星不稳定性的遗传性或散发性结直肠肿瘤中的效用。然而,这些研究的目的不同,针对的患者群体也不同。这些免疫组织化学数据的解读依赖于对影响MMR蛋白检测的生物学和技术因素的透彻理解。在本综述中,我们分析了已发表研究的数据,指出了影响MMR蛋白免疫组织化学检测的各种因素,并预测了免疫组织化学在不同临床环境中的效用。